Jounce Therapeutics (NASDAQ:JNCE) reported Q4 2017 earnings this Morning, coming in at ($0.29) per share, beating Wall Street’s estimates of ($0.31) per Share. Revenue for the quarter came in at $13.00 million missing the streets estimates of $14.95 million
Analyst Coverage For Jounce Therapeutics (NASDAQ:JNCE)
These are 0 Sell Rating(s)
0 Hold Rating(s)
3 Buy Rating(s)
0 Strong Buy Rating(s) .
The current consensus rating for Jounce Therapeutics (NASDAQ:JNCE) is Jounce Therapeutics Inc (JNCE) Receives Consensus Rating of “Strong Buy” from Analysts
www.americanbankingnews.com – February 27 at 1:24 PM with a consensus target price of Jounce Therapeutics Inc , a potential (JNCE)Recent Insider Trading for Jounce Therapeutics (NASDAQ:JNCE)
- On 3/5/2018 Elizabeth Trehu, Insider, sold 4,545 with an average share price of $21.50 per share and the total transaction amounting to $97,717.50.
- On 3/5/2018 Kimberlee C Drapkin, CFO, sold 5,267 with an average share price of $21.42 per share and the total transaction amounting to $112,819.14.
- On 3/5/2018 Richard /Ca/ Murray, CEO, sold 16,334 with an average share price of $21.43 per share and the total transaction amounting to $350,037.62.
- On 1/26/2018 Barbara Gayle Duncan, Director, sold 4,000 with an average share price of $25.00 per share and the total transaction amounting to $100,000.00.
- On 2/1/2017 Celgene Switzerland Llc, Major Shareholder, bought 625,000 with an average share price of $16.00 per share and the total transaction amounting to $10,000,000.00.
- On 2/1/2017 John Duncan Higgons, Director, bought 6,700 with an average share price of $16.00 per share and the total transaction amounting to $107,200.00.
Recent Trading for Jounce Therapeutics (NASDAQ:JNCE) Shares of Jounce Therapeutics closed the previous trading session at 22.54 up +0.70 3.21% with 22.799999237060547 shares trading hands.